Sign in to view content

Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration

Veeral S. Sheth, MD, MBA, FASRS, FACS

Video
Published 2024

Related

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2022
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more